Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats

被引:43
|
作者
Anderes, KL [1 ]
Luthin, DR [1 ]
Castillo, R [1 ]
Kraynov, EA [1 ]
Castro, M [1 ]
Hood, KN [1 ]
Gregory, ML [1 ]
Pathak, VP [1 ]
Christie, LC [1 ]
Paderes, G [1 ]
Vazir, H [1 ]
Ye, Q [1 ]
Anderson, MB [1 ]
May, JM [1 ]
机构
[1] La Jolla Agouron Pharmaceut Inc, Pfizer Global Res & Dev, Res Pharmacol, San Diego, CA 92121 USA
关键词
D O I
10.1124/jpet.102.046656
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gonadotropin-releasing hormone ( GnRH) receptor antagonists have potential in treating numerous hormone-dependent pathologies including cancers of the prostate, breast, and ovary, endometriosis, and fertility disorders. An unmet clinical need exists for an orally available GnRH receptor antagonist. Guided by structure-activity relationships, ligand-based targeted library designs, and biomarker measurements, our discovery efforts have yielded a novel, small molecule GnRH receptor antagonist, 5-[(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthalenyl) methyl]-N-(2,4,6-trimethoxyphenyl)-2-furamide (CMPD1). CMPD1 bound with low nanomolar affinities to human, rat, and mouse GnRH receptors (6.0, 3.8, and 2.2 nM, respectively). CMPD1 was more than 100-fold selective for GnRH receptors versus various G-protein-coupled receptors and other enzymes and ion channels. In cells expressing recombinant rat GnRH receptors, CMPD1 was a competitive antagonist of GnRH-stimulated increases in extracellular acidification rates in Cytosensor microphysiometer assays. In cells expressing recombinant human GnRH receptors, CMPD1 was a potent inhibitor of GnRH-stimulated total inositol phosphate accumulation. The effects of CMPD1 on circulating levels of luteinizing hormone (LH) and testosterone were studied in castrated and intact male rats, respectively. Intravenous and oral administration of CMPD1 dose dependently suppressed GnRH-mediated elevations of LH in castrated male rats and testosterone in gonadintact male rats. Moreover, CMPD1, when given at 20 mg/kg i.v. to intact male rats, inhibited the elevations of LH and testosterone stimulated by the superagonist of GnRH, [D-Ala(6), desGly(10)] GnRH ( GnRH-A). These data suggest that CMPD1 is a potent, selective, orally active GnRH receptor antagonist that may have potential application as a therapeutic agent for treating hormone-dependent cancers and diseases.
引用
收藏
页码:688 / 695
页数:8
相关论文
共 50 条
  • [1] Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist
    Li, Haitao
    Anderes, Kenna L.
    Kraynov, Eugenia A.
    Luthin, David R.
    Do, Quyen-Quyen
    Hong, Yufeng
    Tompkins, Eileen
    Sun, Eric T.
    Rajapakse, Ranjan
    Pathak, Ved P.
    Christie, Lance C.
    Vazir, Haresh
    Castillo, Rosemary
    Gregory, Margaret L.
    Castro, Mary
    Nared-Hood, Karen
    Paderes, Genevieve
    Anderson, Mark B.
    JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (11) : 3362 - 3367
  • [2] Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist. (vol 49, pg 3362, 2006)
    Li, Haitao
    Anderes, Kenna L.
    Kraynov, Eugenia A.
    Luthin, David R.
    Do, Quyen-Quyen
    Hong, Yufeng
    Tompkins, Eileen
    Sun, Eric T.
    Rajapakse, Ranjan
    Pathak, Ved P.
    Christie, Lance C.
    Feng, Jun
    Vazir, Haresh
    Castillo, Rosemary
    Gregory, Margaret L.
    Castro, Mary
    Nared-Hood, Karen
    Paderes, Genevieve
    Anderson, Mark B.
    JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (19) : 5849 - 5849
  • [3] At last, an orally active gonadotropin-releasing hormone antagonist
    Paulson, Richard J.
    FERTILITY AND STERILITY, 2019, 111 (01) : 30 - 31
  • [4] Synthesis of orally active small-molecule gonadotropin-releasing hormone antagonists
    Tucci, FC
    Chen, C
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2004, 7 (06) : 832 - 847
  • [5] Pharmacological characterization of linzagolix, a novel, orally active, non-peptide antagonist of gonadotropin-releasing hormone receptors
    Tezuka, Motohiro
    Tamai, Yasuaki
    Kuramochi, Yu
    Kobayashi, Kaoru
    Fushimi, Nobuhiko
    Kiguchi, Sumiyoshi
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2022, 49 (10) : 1082 - 1093
  • [6] In vivo characterization of a novel GnRH (gonadotropin-releasing hormone) antagonist, LXT-101, in normal male rats
    Chi, Xiaoli
    Zhou, Wenxia
    Cheng, Junping
    Zhang, Yongxiang
    Liu, Keliang
    REGULATORY PEPTIDES, 2006, 136 (1-3) : 122 - 129
  • [7] The structure and biological functions of gonadotropin-releasing hormone (GnRH)
    Ye, D
    Pan, JW
    Liao, MJ
    Zhang, ZH
    Zhu, MY
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2003, 30 (01) : 49 - 53
  • [8] SYNTHESIS OF A NEW CYCLIC GONADOTROPIN-RELEASING HORMONE (GNRH) ANTAGONIST
    KUPRYSZEWSKI, G
    RIVIER, CL
    PERRIN, M
    VALE, WW
    RIVIER, JE
    POLISH JOURNAL OF CHEMISTRY, 1987, 61 (4-6) : 627 - 630
  • [9] Discovery of an Orally Bioavailable Gonadotropin-Releasing Hormone Receptor Antagonist
    Kim, Seon-Mi
    Lee, Minhee
    Lee, So Young
    Park, Euisun
    Lee, Soo-Min
    Kim, Eun Jeong
    Han, Min Young
    Yoo, Taekyung
    Ann, Jihyae
    Yoon, Suyoung
    Lee, Jiyoun
    Lee, Jeewoo
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (19) : 9150 - 9172
  • [10] Novel peptidomimetics related to gonadotropin-releasing hormone (GnRH)
    Gelain, Arianna
    Rizzi, Luca
    Legnani, Laura
    Pacini, Aurora
    Spyridaki, Katerina
    Karageorgos, Vlasios
    Liapakis, George
    Villa, Stefania
    MEDCHEMCOMM, 2015, 6 (09) : 1656 - 1665